AstraZeneca - ATTEST
Association of the risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID19 vaccines
To evaluate an association between COVID19 vaccine exposure and thromboembolic events occurring with thrombocytopenia (thrombotic thrombocytopenia syndrome; TTS)
Report to regulators and scientific publications
The project will shed more light on the safety of the AstraZeneca and Pfizer COVID-19 vaccines
How does this research try to address the problem?
Using the ORCHID RCGP RSC primary care data linked to national secondary care hospital admissions, ONS mortality, vaccination and testing data, we will design a matched case-control study and a self-controlled case series to learn about the safety of the AstraZeneca and Pfizer vaccines.
How we are planning to implement the research outputs
The findings of these analyses will be compiled in a report to the regulators and various scientific publications.
External project members
Project end date
The analyses are complete. The report to the regulators is expected to be completed in June 2023, scientific publications during the summer of 2023
Partners on this project